Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease

Rivaroxaban is approved in various regions for the treatment of acute venous thromboembolism (VTE) in children aged between 0 and 18 years and was recently investigated for thromboprophylaxis in children aged between 2 and 8 years (with body weights <30 kg) with congenital heart disease who had u...

Descripción completa

Detalles Bibliográficos
Autores principales: Willmann, Stefan, Ince, Ibrahim, Ahsman, Maurice, Coboeken, Katrin, Zhang, Yang, Thelen, Kirstin, Kubitza, Dagmar, Zannikos, Peter, Zhou, Wangda, Pina, Liza Miriam, Post, Teun, Lippert, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381895/
https://www.ncbi.nlm.nih.gov/pubmed/35665486
http://dx.doi.org/10.1002/psp4.12830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381895/
https://www.ncbi.nlm.nih.gov/pubmed/35665486
http://dx.doi.org/10.1002/psp4.12830

Ejemplares similares